Trial Profile
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs BP 1002 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bio-Path Holdings
- 20 Feb 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
- 10 Jan 2024 According to a Bio-Path Holdings media release, enrollment is now open for patients for the second dose cohort of 40 mg/m2.
- 10 Jan 2024 According to a Bio-Path Holdings media release, trial is being conducted at several leading cancer centers, including the Georgia Cancer Center, The University of Texas Southwest and New York Medical College. Locke Bryan, M.D., Associate Professor of Medicine at the Georgia Cancer Center, is serving as National Principal Investigator for the Phase 1 trial.